• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2010 Update: Guidelines for the management of benign prostatic hyperplasia.

作者信息

Nickel J Curtis, Méndez-Probst Carlos E, Whelan Thomas F, Paterson Ryan F, Razvi Hassan

机构信息

Queen's University, Kingston, ON;

出版信息

Can Urol Assoc J. 2010 Oct;4(5):310-6. doi: 10.5489/cuaj.10124.

DOI:10.5489/cuaj.10124
PMID:20944799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2950766/
Abstract
摘要

相似文献

1
2010 Update: Guidelines for the management of benign prostatic hyperplasia.2010年更新版：良性前列腺增生管理指南
Can Urol Assoc J. 2010 Oct;4(5):310-6. doi: 10.5489/cuaj.10124.
2
Translation of benign prostatic hyperplasia guidelines into clinical practice.良性前列腺增生症指南在临床实践中的转化
Curr Opin Urol. 2008 Jan;18(1):56-60. doi: 10.1097/MOU.0b013e3282f13bbf.
3
[Evaluation of the impact of CTMH guidelines on the management of benign prostatic hyperplasia].[CTMH指南对良性前列腺增生管理的影响评估]
Prog Urol. 2015 Jan;25(1):47-53. doi: 10.1016/j.purol.2014.09.049.
4
Investigation of benign prostatic hyperplasia.良性前列腺增生的研究
Curr Opin Urol. 2003 Jan;13(1):17-22. doi: 10.1097/00042307-200301000-00004.
5
[Surgical and interventional management of benign prostatic obstruction: Guidelines from the Committee for Male Voiding Disorders of the French Urology Association].[良性前列腺梗阻的外科及介入治疗管理：法国泌尿外科学会男性排尿障碍委员会指南]
Prog Urol. 2021 Apr;31(5):249-265. doi: 10.1016/j.purol.2020.12.006. Epub 2021 Jan 18.
6
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry.泌尿科医生和初级保健医生对良性前列腺增生的评估和管理：来自观察性 BPH 登记处的实践模式。
J Urol. 2011 Sep;186(3):971-6. doi: 10.1016/j.juro.2011.04.081. Epub 2011 Jul 24.
7
An observational analysis of provider adherence to AUA guidelines on the management of benign prostatic hyperplasia.对医疗服务提供者遵循美国泌尿外科学会良性前列腺增生管理指南情况的观察性分析。
J Urol. 2014 Nov;192(5):1483-8. doi: 10.1016/j.juro.2014.06.016. Epub 2014 Jun 12.
8
Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia.男性下尿路症状和良性前列腺增生临床指南。
Int J Urol. 2017 Oct;24(10):716-729. doi: 10.1111/iju.13401. Epub 2017 Jul 26.
9
Holmium laser treatment of benign prostatic hyperplasia: an update.钬激光治疗良性前列腺增生：最新进展
Curr Opin Urol. 2007 Jan;17(1):27-31. doi: 10.1097/MOU.0b013e3280111447.
10
A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.一种针对良性前列腺增生新型血清生物标志物的综合方法：MPSA 联盟。
J Urol. 2008 Apr;179(4):1243-56. doi: 10.1016/j.juro.2007.11.049. Epub 2008 Feb 20.

引用本文的文献

1
Outcomes of Prostatic Artery Embolization for Treating Benign Prostatic Hyperplasia Symptoms: A Prospective Single-Center Study.经前列腺动脉栓塞术治疗良性前列腺增生症状的疗效：一项前瞻性单中心研究。
Health Sci Rep. 2025 Mar 11;8(3):e70565. doi: 10.1002/hsr2.70565. eCollection 2025 Mar.
2
Alpha-adrenergic antagonists and iris dynamics: Challenges and solutions in cataract surgery.α-肾上腺素能拮抗剂与虹膜动力学：白内障手术中的挑战与解决方案。
BMC Ophthalmol. 2024 Oct 3;24(1):431. doi: 10.1186/s12886-024-03705-1.
3
Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.5α还原酶抑制剂与良性前列腺增生男性患前列腺癌的风险：一项利用初级保健数据的历史性队列研究。
Wellcome Open Res. 2023 Jul 11;8:295. doi: 10.12688/wellcomeopenres.19566.1. eCollection 2023.
4
Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis.α受体阻滞剂单药治疗良性前列腺增生症的疗效和安全性比较：系统评价和网络荟萃分析。
Sci Rep. 2024 May 15;14(1):11116. doi: 10.1038/s41598-024-61977-5.
5
Safety of transurethral resection of large prostate.经尿道大前列腺切除术的安全性
Urol Ann. 2023 Apr-Jun;15(2):162-165. doi: 10.4103/ua.ua_192_21. Epub 2023 Jan 16.
6
C.A. meyer alleviates benign prostatic hyperplasia while preventing finasteride-induced side effects.C.A. 迈耶在预防非那雄胺引起的副作用的同时减轻良性前列腺增生。
Front Pharmacol. 2023 Jan 12;14:1039622. doi: 10.3389/fphar.2023.1039622. eCollection 2023.
7
Risk of prostate cancer and death after benign transurethral resection of the prostate-A 20-year population-based analysis.良性经尿道前列腺切除术（TURP）后前列腺癌风险和死亡的 20 年基于人群的分析。
Cancer. 2022 Oct;128(20):3674-3680. doi: 10.1002/cncr.34407. Epub 2022 Aug 17.
8
UPDATE - Canadian Urological Association guideline: Male lower urinary tract symptoms/benign prostatic hyperplasia.更新 - 加拿大泌尿外科协会指南：男性下尿路症状/良性前列腺增生
Can Urol Assoc J. 2022 Aug;16(8):245-256. doi: 10.5489/cuaj.7906.
9
The role of preoperative dutasteride in reducing bleeding during transurethral resection of the prostate: A systematic review and meta-analysis of randomized controlled trials.术前度他雄胺在经尿道前列腺切除术中减少出血的作用：一项随机对照试验的系统评价和荟萃分析
Asian J Urol. 2022 Jan;9(1):18-26. doi: 10.1016/j.ajur.2021.05.011. Epub 2021 Jun 8.
10
Real-world therapeutic management and evolution of patients with benign prostatic hyperplasia in primary care and urology in Spain.西班牙初级保健和泌尿科中良性前列腺增生患者的真实世界治疗管理和演变。
Int J Clin Pract. 2021 Aug;75(8):e14250. doi: 10.1111/ijcp.14250. Epub 2021 May 29.

本文引用的文献

1
Effect of dutasteride on the risk of prostate cancer.度他雄胺对前列腺癌风险的影响。
N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.
2
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.5α-还原酶抑制剂用于前列腺癌化学预防：美国临床肿瘤学会/美国泌尿外科学会2008年临床实践指南
J Urol. 2009 Apr;181(4):1642-57. doi: 10.1016/j.juro.2009.01.071. Epub 2009 Feb 26.
3
Photoselective vaporization of prostate: five-year outcomes of entire clinic patient population.前列腺光选择性汽化术：整个临床患者群体的五年结果
Urology. 2009 Apr;73(4):807-10. doi: 10.1016/j.urology.2008.08.502. Epub 2009 Feb 5.
4
Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers.非那雄胺单药治疗可使良性前列腺增生男性在停用α受体阻滞剂后维持稳定的下尿路症状。
Can Urol Assoc J. 2008 Feb;2(1):16-21. doi: 10.5489/cuaj.520.
5
Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression.前列腺特异性抗原及前列腺特异性抗原衍生物作为良性前列腺增生进展的预测指标
Curr Urol Rep. 2007 Jul;8(4):269-74. doi: 10.1007/s11934-007-0072-y.
6
Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.在临床实践环境中，国际前列腺症状评分困扰问题与良性前列腺增生影响指数的相关性。
BJU Int. 2008 Jun;101(12):1531-5. doi: 10.1111/j.1464-410X.2008.07574.x. Epub 2008 Apr 28.
7
The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.度他雄胺、坦索罗辛及联合治疗对良性前列腺增生和前列腺肿大男性下尿路症状的影响：CombAT研究的2年结果
J Urol. 2008 Feb;179(2):616-21; discussion 621. doi: 10.1016/j.juro.2007.09.084. Epub 2007 Dec 21.
8
Bipolar transurethral resection in saline--an alternative surgical treatment for bladder outlet obstruction?盐水介质下双极经尿道切除术——膀胱出口梗阻的一种替代性手术治疗方法？
J Urol. 2007 Nov;178(5):2035-9; discussion 2039. doi: 10.1016/j.juro.2007.07.038. Epub 2007 Sep 17.
9
The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study.基于人群的男性前列腺体积实际变化与下尿路症状严重程度显著变化之间的长期关系：克林彭研究
Eur Urol. 2008 Apr;53(4):819-25; discussion 825-7. doi: 10.1016/j.eururo.2007.08.042. Epub 2007 Aug 28.
10
The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics.良性前列腺增生症登记与患者调查：研究设计、方法及患者基线特征
BJU Int. 2007 Oct;100(4):813-9. doi: 10.1111/j.1464-410X.2007.07061.x.